Omnimmune Holdings, Inc. (OMMH) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Houston, 미국. 현재 CEO는 Howard Becker.
OMMH 을(를) 보유 IPO 날짜 2022-12-30, 2 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $981.00.
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
